Founded with a mission to save lives, our world-class team of cardiology and technology experts drive our vision for better detection of a major worldwide killer – coronary artery disease.
We are Australian.
Artrya is an AI-driven health-tech company, founded in 2019, and brought to life on the shores of Perth, Australia. Artrya was developed by John Konstantopoulos and John Barrington AM, who came together with a mutual passion for disruptive technologies and improving health outcomes across the globe. Artrya sees heart disease in a new way, using data-driven solutions to assist cardiovascular diagnosis.
We are pioneers.
We are forging a new way to detect the fatal cause of heart attacks, which is vulnerable plaque 1. We are doing it in a way that is better for patients, more effective for healthcare professionals and more efficient for healthcare systems.
We know heart disease diagnosis is not optimal.
Heart disease diagnosis has not changed significantly in more than 50 years. That’s two generations that have continued to be in the dark about the real cause of heart disease deaths. Traditional diagnostic processes to assess stenosis have avoided sophisticated analysis because it was time-consuming and required significant manual inputs.
We are changing that.
Our AI-solution helps bring the benefits of new and emerging diagnostic metrics to clinical practice. This is changing the diagnostic paradigm.
We are shining a light on cardiovascular diagnosis.
We want to bring about nothing less than a transformation of cardiovascular disease care.
Artrya. Your partner in AI-driven healthcare.
What we do
Artrya is an Australian health-tech company, founded in 2019. We see heart disease in a new way, using data-driven solutions to assist cardiovascular diagnosis.
We collaborate with radiologists, cardiologists, and healthcare professionals to provide personalised cardiovascular-health risk assessments within minutes. Our innovative diagnostic support solution accurately assesses and detects vulnerable, high-risk plaque, in real time, without the need for invasive interventions.
We enable the risk stratification of patients and with this, provide a prioritisation tool to clinicians so they can get the right treatment to the right patient at the right time. This early indication of the superior predictor of heart attack, and near-immediate pathway to the right treatment option, has the potential to reduce the number of major adverse cardiac events each year.
Our safe and non-invasive heart-disease solution will allow improved access to informed decision-making for cardiologists and patients.
Accurate. Safe. Fast. Life-saving.
The heart behind our name
Meaning of Artrya
Artrya is a play on words of ‘artery,’ the vessel which takes oxygen-rich blood from the heart to other parts of the body. It is based on the Greek word aρτηρiα (arteria) meaning ‘air’ and ‘to keep’. This underpins our mission to use advanced, AI-based technology to reduce the number of heart attacks that occur around the world each year and, fundamentally, save lives.
January - Founded as a collaboration with the University of Western Australia and the Harry Perkins Institute of Medical Research, based in Australia.
May – $1m raised from Angel investors.
May – $2.8m raised from Seed investors.
Jul - Received $1 million in funding from the Australian Government’s Medical Research Future Fund BioMedTech Horizons Program, chosen as one of 10 from 169 applicants.
Nov – Granted Therapeutic Goods Australia (TGA) regulatory clearance to launch Salix to detect arterial abnormalities assisting healthcare professionals to make a diagnosis.
March – Achieved ISO 13485 and MDSAP certifications.
April – Commenced Salix 1.1 market trial at Envision Medical Imaging.
May – Raised AUD 15 million from institutional investors.
August – Released Salix 1.2 to commence national pilots.
November – Announced partnership with EVERSANA to launch and commercialise in the UK.
November – Listed on the Australian Securities Exchange.
Artrya acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.
We acknowledge the Whadjuk Noongar people, Traditional Custodians of the land on which the Artrya office operates.
Artrya Salix has been developed with funding from MTPConnect, an Australian incubator for medical technologies. Other private investors have also assisted with research and development funding.
- Williams, Michelle, et all. 2020. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results from the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 141. 10.1161/CIRCULATIONAHA.119.044720.